Advertisement

Clinical Implications of Head and Neck Cancer

  • Panagiota Economopoulou
  • Amanda K. Psyrri
Chapter

Abstract

The survival of tobacco-associated Head and Neck Squamous Cell Carcinoma (HNSCC) has not substantially changed over the past 30 years. Novel agents and strategies are being tested in several clinical trials. Quantitative imaging using computed tomography, magnetic resonance imaging, and positron emission tomography modalities plays a pivotal role in the design of clinical trials addressing molecularly targeted therapies.

References

  1. 1.
    Kurland BF, Gerstner ER, Mountz JM et al (2012) Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging 30:1301–1312CrossRefGoogle Scholar
  2. 2.
    Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856–1867CrossRefGoogle Scholar
  3. 3.
    Seiwert TY, Burtness B, Mehra R et al (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17(7):956–965CrossRefGoogle Scholar
  4. 4.
    2010 ACSCFaFACSGoogle Scholar
  5. 5.
    Cabanillas ME, Hu MI, Durand JB, Busaidy NL (2011) Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780CrossRefGoogle Scholar
  6. 6.
    Bible KC, Suman VJ, Molina JR et al (2010) Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 11:962–972CrossRefGoogle Scholar
  7. 7.
    Carr LL, Mankoff DA, Goulart BH et al (2010) Phase II study of daily sunitinib in FDG-PET-positive, iodine- refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260–5268CrossRefGoogle Scholar
  8. 8.
    Kloos RT, Ringel MD, Knopp MV et al (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675–1684CrossRefGoogle Scholar
  9. 9.
    Wells SA Jr, Gosnell JE, Gagel RF et al (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767–772CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.2nd Department of Interna Medicine, Section of Medical OncologyAttikon University HospitalAthensGreece

Personalised recommendations